- Home
- EIM vs FENC Comparison
EIM vs FENC Comparison
Compare EIM & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EIM | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 411.0M |
| IPO Year | 2002 | 2010 |
Fundamental Metrics
Financial Performance| Metric | EIM | FENC |
|---|---|---|
| Price | $9.68 | $11.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 144.4K | ★ 184.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $195.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.48 | $5.65 |
| 52 Week High | $10.54 | $13.25 |
Technical Indicators
Market Signals| Indicator | EIM | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 57.00 |
| Support Level | $9.67 | $9.74 |
| Resistance Level | $10.01 | N/A |
| Average True Range (ATR) | 0.07 | 0.65 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 44.25 | 37.75 |
Price Performance
Historical ComparisonAbout EIM Eaton Vance Municipal Bond
Eaton Vance Municipal Bond Fund is a non-diversified closed-end management investment company. It consists of Municipal bond fund, California municipal bond fund, and New York municipal bond fund. The company's investment objective is to provide current income exempt from regular federal income tax, alternative minimum tax, and taxes in specified states. Its investment plan is to invest in higher quality bonds.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.